Shield Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Shield Therapeutics CEO'su Anders Lundstrom, Jul2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.001% doğrudan sahiptir ve bu hisselerin değeri £ 300.31 dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 4 yıldır.
Anahtar bilgiler
Anders Lundstrom
İcra Kurulu Başkanı
US$53.5k
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | less than a year |
| CEO sahipliği | 0.001% |
| Yönetim ortalama görev süresi | 1.6yrs |
| Yönetim Kurulu ortalama görev süresi | 4yrs |
Son yönetim güncellemeleri
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15CEO
Anders Lundstrom (62 yo)
less than a year
Görev süresi
US$53,542
Tazminat
Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | less than a year | US$53.54k | 0.0013% £ 300.3 | |
| Co-Founder & Non Executive Director | 16.8yrs | US$47.17k | 1.49% £ 349.6k | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| General Counsel & Company Secretary | 7.2yrs | Veri yok | Veri yok | |
| Group HR Director | no data | Veri yok | Veri yok | |
| Head of Pharmacovigilance & Medical Information | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 1.6yrs | Veri yok | Veri yok | |
| Senior Director of People & Culture | no data | Veri yok | Veri yok |
1.6yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: STX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | 3.5yrs | US$53.54k | 0.0013% £ 300.3 | |
| Co-Founder & Non Executive Director | 4.4yrs | US$47.17k | 1.49% £ 349.6k | |
| Independent Non Executive Chairman | 6.3yrs | US$119.83k | 0.70% £ 165.0k | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | 8.8yrs | US$76.49k | 0.023% £ 5.3k | |
| Notable Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 3.5yrs | US$47.17k | 0.035% £ 8.2k | |
| Notable Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Notable Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Notable Scientific Advisory Board | no data | Veri yok | Veri yok |
4.0yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: STX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).